Kolaviron attenuates Dextran sulphate sodium-induced colitis by enhancing the expression of MUC-2
Naunyn-Schmiedeberg's Archives of Pharmacology · 2025
DOI: 10.1007/s00210-025-04895-1 ↗Kurz gefasst
Fachartikel in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, 2025. Verfasst von Adeoti G Adeniran und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology, Faculty of Basic Medical Sciences, University of Medical Sciences, Ondo City, Ondo State, Nigeria. Hauptthemen laut MEDLINE: Mucin-2, Flavonoids, Anti-Inflammatory Agents, Colitis. Die Arbeit nennt 49 Literaturangaben.
Abstract (Originalsprache)
Ulcerative colitis, a chronic inflammatory bowel disease, is a complex and multifactorial disease with unknown etiology that remains challenging in its management due to pathophysiological complexity and limited success with conventional therapies such as 5-aminosalicylic acid, corticosteroids, and anti-TNF-α antibodies. This study examines the therapeutic potential of Kolaviron, a biflavonoid complex from Garcinia kola, with a novel focus on its effect on colonic MUC-2 expression, a key component of the intestinal mucus barrier, together with its known antioxidant and anti-inflammatory actions in dextran sulphate sodium (DSS)-induced colitis in a Wistar rat model. Rats were randomly divided into 4 groups (n = 5 per group): Group 1 (Control) received vehicle (DMSO); Groups 2, 3, and 4 were administered 5% (w/v) DSS orally and received DMSO, kolaviron, or sulfasalazine (200 mg/kg), respectively. Kolaviron significantly reduced disease activity index, oxidative stress markers, myeloperoxidase activity, TNF-α, IL-6, and lipid peroxidation. It also improved colonic histoarchitecture and remarkably enhanced the expression of MUC-2. In silico docking analysis showed strong binding affinities of Kolaviron to NF-κB and phospholipase C, pointing to its contribution in the regulation of molecular pathways for MUC-2 expression. Kolaviron significantly reduced the disease activity index and colonic oxidative stress by enhancing antioxidant levels and decreasing myeloperoxidase activity, tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and lipid peroxidation, with the novel enhancement of MUC-2 expression, highlighting its potential role in restoring mucosal barrier integrity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Physiology, Faculty of Basic Medical Sciences, University of Medical Sciences, Ondo City, Ondo State, Nigeria.
- Department of Physiology, Faculty of Basic Medical Sciences, University of Medical Sciences, Ondo City, Ondo State, Nigeria. bomolaso@unimed.edu.ng.
- Department of Biochemistry, Faculty of Basic Medical Sciences, University of Medical Sciences, Ondo City, Ondo State, Nigeria.
Zitieren
APA
Adeniran, A. G., Omolaso, B. O., Afuye, M. O., Fagbire, I. D., Richard, S. A., Olabimtan, A., Akinrinsola, R. A., Adewole, K. E., Ogunmiluyi, O. E., & Adebimpe, A. F. (2025). Kolaviron attenuates Dextran sulphate sodium-induced colitis by enhancing the expression of MUC-2. Naunyn-Schmiedeberg's Archives of Pharmacology. https://doi.org/10.1007/s00210-025-04895-1
Vancouver
Adeniran AG, Omolaso BO, Afuye MO, Fagbire ID, Richard SA, Olabimtan A, et al. Kolaviron attenuates Dextran sulphate sodium-induced colitis by enhancing the expression of MUC-2. Naunyn-Schmiedeberg's Archives of Pharmacology. 2025. doi:10.1007/s00210-025-04895-1
BibTeX
@article{Adeniran2025,
author = {Adeniran, Adeoti G and Omolaso, Blessing O and Afuye, Motunrayo O and Fagbire, Ifeoluwa D and Richard, Similoluwa A and Olabimtan, Anjolaoluwa and Akinrinsola, Rexona A and Adewole, Kayode E and Ogunmiluyi, Oluwafunmbi Ebenezer and Adebimpe, Adedayo Faith},
title = {Kolaviron attenuates Dextran sulphate sodium-induced colitis by enhancing the expression of MUC-2},
journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
year = {2025},
doi = {10.1007/s00210-025-04895-1}
}
EUVIMED